MUC1 and adenocarcinoma: In addition to the ADC approach, another potential strategy is to exploit the cancer-specific glycoform of MUC21 for engineered immune cell therapies, such as CAR-T cell therapy targeting the cancer associated Tn (GalNAca1-O-Ser/Thr)-glycoform of MUC1 to control various adenocarcinomas [47].